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Abstract
It has been shown that angiogenesis and inflammation play an important role in development of 
most hematological malignancies including the myeloproliferative neoplasm (MPN). The aim of 
this study was to investigate and correlate the levels of key angiogenic molecules such as hypoxia-
inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and endothelial nitric 
oxide synthase (eNOS) in peripheral blood and bone marrow cells of MPN patients, along with 
JAK2V617F mutation allele burden and effects of therapy. HIF-1α and VEGF gene expression 
were decreased, while eNOS mRNA levels were increased in granulocytes of MPN patients. 
Furthermore, positively correlated and increased VEGF and eNOS protein levels were in negative 
correlation with HIF-α levels in granulocytes of MPN patients. According to immunoblotting, the 
generally augmented angiogenic factors demonstrated JAK2V617F allele burden dependence only 
in granulocytes of PMF. The angiogenic factors were largely reduced after hydroxyurea therapy in 
granulocytes of MPN patients. Levels of eNOS protein expression were stimulated by Calreticulin 
mutations in granulocytes of essential thrombocythemia. Immunocytochemical analyses of CD34+ 
cells showed a more pronounced enhancement of angiogenic factors than in granulocytes. 
Increased gene expression linked to the proinflammatory TGFβ and MAPK signaling pathways 
were detected in CD34+ cells of MPN patients. In conclusion, the angiogenesis is increased in 
several cell types of MPN patients supported by the transcriptional activation of inflammation-
related target genes, and is not limited to bone marrow stroma cells. It also appears that some of 
the benefit of hydroxyurea therapy of the MPN is mediated by effects on angiogenic factors.
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INTRODUCTION
Angiogenesis is a process of generation of new capillaries, and increased levels of 
angiogenic factors reflect the aggressiveness of tumor cells [1]. Many inducers of 
angiogenesis have been identified but one of the best characterized is vascular endothelial 
growth factor (VEGF) [2]. One of the most potent stimuli for increased VEGF production by 
tumor cells, in vitro and in vivo, is hypoxia via the hypoxia-inducible factor-1 alpha 
(HIF-1α) [3]. Recent studies have correlated HIF-1α with VEGF gene expression in cancers 
and myeloma cells [4,5]. The role of nitric oxide (NO) in angiogenesis is controversial since 
several studies have revealed that NO may induce VEGF production via the 
phosphoinositide-3-kinase (PI3K)/AKT/HIF-1α pathway [6], while others reported that NO 
might act as an inhibitor of HIF-1α [7]. These contradictory data indicate that NO effects 
may depend on the redox state of the cellular environment and cell type specific response 
[8]. Low concentrations of NO produced in response to VEGF stimulated angiogenesis, 
while higher concentrations associated with inflammation can inhibit angiogenesis [9].
Myeloproliferative neoplasms (MPNs) include three major entities: polycythemia vera (PV), 
essential thrombocythemia (ET), and primary myelofibrosis (PMF). They are clonal 
disorders arising in a pluripotent hematopoietic stem cell, causing an unregulated increase of 
terminally differentiated blood cells, with an increased risk of thrombosis and late 
transformation to acute myeloid leukemia [10]. Common feature of these diseases is 
acquired somatic mutation V617F in the JAK2 gene, present in 97% of patients with PV and 
half of the patients with ET and PMF [11]. Increased microvessel density and VEGF 
expression associated with MPNs was further enhanced with high JAK2V617F mutant allele 
burden [12]. Nevertheless, the levels of VEGF in ET patients on hydroxyurea therapy were 
significantly lower than in untreated ET patients [13].
The human cell surface molecule CD34 is expressed on hematopoietic and vascular 
endothelial progenitor cells, while capillaries of most tissues are CD34+ [14]. These bone 
marrow derived CD34+ cells are found circulating in peripheral blood and their efficacy in 
proangiogenic therapies has been studied [15]. In contrast to the typical cobblestone 
morphology of endothelial cells, CD3+ endothelial cells are more elongated and lack tight 
junctions. These CD34+ endothelial cells have the prominent impact during in vivo 
angiogenesis [16].
In hematological malignancies, bone marrow and lymphatic organs harbor the malignant 
clone that gives rise to disease, followed with imbalance of the cells, cytokines and growth 
factors maintaining physiological angiogenesis [17]. During the last decade, angiogenesis 
was shown to play an important role in the development of most hematological malignancies 
[18]. The aim of the present study was to investigate and correlate the levels of key 
angiogenic molecules HIF-1α, VEGF, and endothelial NO synthase (eNOS) in bone 
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marrow, CD34+ cells and granulocytes of MPNs, according to JAK2V617F and Calreticulin 
(CALR) mutation status and therapy.
MATERIALS AND METHODS
Patients and Controls
This study includes 160 patients and 15 healthy controls. Patients were diagnosed with MPN 
according to the World Health Organization classification. All patients had signed the 
consent form approved by the institutional review board. The median age of patients, 
comprising 70 males and 90 females, was 48.5 yr (range: 27–90 yr) at the time of diagnosis, 
while the median age of healthy donors, comprising 10 males and 5 females, was 49 years 
(range: 30–70 yr). From 160 patients included in our study, 72 were classified as PV, 47 as 
ET, and 41 as PMF. Of 72 PV patients, 28 were homozygotes while 44 heterozygous for 
JAK2V617F mutation. From 47 ET patients, 22 were without JAK2 mutation and 25 
heterozygous. Finally, from 41 PMF patients, 16 were without JAK2 mutation, 8 
homozygotes, and 17 heterozygous.
Isolation of CD34+ Cells and Granulocytes From the Peripheral Blood of MPN Patients
All de novo patients were subject to 30 ml of peripheral blood draw on one occasion, 
collected in disodium ethylenediaminetetraacetic acid (EDTA). The CD34+ cells were 
isolated from the collected mononuclear cells using a magnetic separation column (Super 
Macs II, Miltenyi Biotec, Bergisch Gladbach, Germany) and a mixture of magnetic 
microbeads conjugated with antibody against CD34 (Miltenyi Biotec) according to the 
manufacturer’s instructions. The pellet formed during centrifugation with lymphocyte 
separation medium (LSM, PAA Laboratories GmbH, Pasching, Austria), is comprised 
mostly of erythrocytes and granulocytes. Erythrocytes were removed by using lysing 
solution (0.15 M NH4Cl, 0.1 mM Na2EDTA, 12 mM NaHCO3). The viable CD34+ cell and 
granulocyte were counted by a trypan-blue exclusion technique (Life Technologies, 
Bleiswijk, Netherlands).
DNA Sequencing
Genomic DNA was extracted from peripheral blood granulocytes of MPN patients by using 
the proteinase K and phenol-chloroform technique. Single nucleotide mutation JAK2V617F 
was characterized by DNA sequencing after PCR amplification. PCR amplification was 
performed with wild-type JAK2-specific forward primer 5’-
TGGCAGAGAGAATTTTCTGAACT-3’ and reverse primer 5’-
TTCATTGCTTTCCTTTTTCACA-3’, confirmed by electrophoresis on an ethidium 
bromide-impregnated 1% agarose gel. PCR amplified samples are analyzed by sequencing 
on an automated ABI PRISM 3130 Genetic Analyzer (Applied Biosystems Inc, Foster City, 
CA) with AB DNA Sequencing Analysis Software (v 5.2) by using the Big Dye Terminator 
v3.1 Ready Reaction Cycle Sequencing Kit.
The mutation analysis of CALR exon 9, −52bp deletion (type1) and +5bp insertion (type2), 
was performed by allele specific PCR as previously reported [19]. The primer sequences are 
5’−3’sequence CALR-intr8-fam-fwd FAM-GGCAAGGCCCTGAGGTGT and CALR-ex9-
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rev GGCCTCAGTCCAGCCCTG. The PCR products were analyzed by fragment analysis 
with ABI3130xl Genetic Analyzer (Applied Biosystems Inc).
Isolation of Total RNA and RT-PCR
Total RNA from CD34+ cells and granulocytes was isolated using TRIzol (Life 
Technologies). Concentration and integrity of total RNA was assessed using Ultrospec 3300 
spectrophotometer (Amersham Pharmacia, Upsala, Sweeden). Equal amounts of RNA from 
different samples were transcribed into cDNA using the Maxima First Strand cDNA 
Synthesis kit (Thermo Fisher Scientific, Waltham, MA).
Real-Time Quantitative PCR
Quantitative real-time PCR analyses of human VEGF gene was performed using a 
LightCycler 480 (Roche Diagnostics, Roche Applied Science, Mannheim, Germany) and 
Taqman oligonucleotide probe 5’ CCA AGT GGT CCC AGG CTG CAC C 3’ and forward 
5’ TTG CTG CTC TAC CTC CAC CAT 3’ and reverse 5’ CAC TTC GTG ATG ATT CTG 
CCC 3’ primers. The oligonucleotide probes were fluorescently labeled on the 5’ end with 
FAM (6-carboxy fluorescein) and on the 3’ end with BlackBerry Quencher (BBQ). 
Quantitative real-time PCR analyses of human HIF-1α gene was performed using 
oligonucleotide probe 5’ AGC AAC AGG GAA AGC GTG GCT 3’ and forward 5’ GGC 
AGG AAG ATT GTC ATG GAC 3’ and reverse 5’ TCT GTC TGT CAC ATG GGT GAT 
GAA 3’ primers (TIB MOLBIOL GmbH, Berlin, Germany). Real-time quantitative PCR of 
eNOS gene was performed on a Mastercycler EP RealPlex (Eppendorf AG, Hamburg, 
Germany) using the Maxima SYBR Green/ROX qPCR master mix (Thermo Scientific, 
Cambridge, UK) and forward: 5’ CGG CAT CAC CAG GAA GAA GA 3’ and reverse 5’ 
GCC ATC ACC GTG CCC AT 3’ primers. β-actin was used as an internal control for 
normalization of the examined angiogenic factors. Real-time PCR was performed in 
granulocytes of total 83 MPN patients, but because of overlapping (samples from the same 
patient): HIF-1α was evaluated in 50 samples (20 PV, 15 ET, 15 PMF, plus 6 controls), 
VEGF in 52 samples (20 PV, 16 ET, 16 PMF, plus 6 controls) and eNOS in 58 samples (20 
PV, 23 ET, 15 PMF, plus 6 controls). Real-time PCR was performed in CD34+ cells of total 
57 MPN patients, but because of overlapping: HIF-1α was evaluated in 36 samples (16 PV, 
11 ET, 9 PMF, plus 5 controls), VEGF in 44 samples (22 PV, 11 ET, 11 PMF, plus 5 
controls), and eNOS in 39 samples (15 PV, 15 ET, 9 PMF, plus 5 controls).
Western Blot
Granulocytes were lysed in chilled radioimmuno precipitation assay (RIPA) lysis buffer (50 
mM Tris-HCl pH 7.6, 150 mM sodium chloride, 1% Triton x-100, 1% sodium deoxycholate, 
0.1% sodium dodecyl sulphate, 2 mM EDTA and 50 mM sodium fluoride) at a ratio of 1 ml 
of buffer on 1 × 108 cells. A protease inhibitor cocktail (Pierce, Thermo Fisher Scientific, 
Waltham, MA) and sodium orthovanadate were added to the lysis buffer just prior to use. 
Lysates were incubated at 4°C for 25 m and then centrifuged at 10 000g, 4°C, for 15 min. 
Protein concentration was determined by the bicinchoninic acid (BCA) Protein Assay Kit 
(Pierce, Thermo Fisher Scientific, Waltham, MA) and samples were stored at −70°C. In 
order to examine activated HIF-1α protein, we conducted separation of the nuclear and 
cytoplasmic fractions of granulocytes using NE-PER Kit (Pierce, Thermo Fisher Scientific). 
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For Western blotting, equal amounts of protein samples were run on polyacrylamide gels 
and transferred to polyvinylidene difluoride membrane. The membrane was blocked with 
5% bovine serum albumin (BSA, Applichem, GmbH, Darmstadt, Germany) for 1 h at room 
temperature (RT) and probed with primary antibodies to HIF-1α (R&D Systems, Abingdon, 
UK), α-tubulin (Sigma–Aldrich, Dorset, UK), VEGF, eNOS, and H2B (Santa Cruz 
Biotechnologies, Dallas, TX). Peroxidase conjugated goat anti-rabbit imunoglobulin (Santa 
Cruz Biotechnologies) and goat anti-mouse imunoglobulin (Pierce, Thermo Fisher 
Scientific), were used as secondary antibodies. Hyperfilm was developed to visualize the 
secondary antibody by the enhanced chemiluminescence reagent system (GE Healthcare, 
Amersham, UK) according to the manufacturer’s instructions. The content of HIF-1α, 
VEGF, and eNOS in cells extracts was estimated by the densitometry of scanned 
immunoblot band using the Image Master Total Lab (GE Healthcare) software. Western 
blotting was performed in granulocytes of total 60 MPN patients, but because of 
overlapping: HIF-1α was evaluated in 42 samples (12 PV, 12 ET, 18 PMF, plus 4 controls), 
VEGF in 49 samples (17 PV, 17 ET, 15 PMF, plus 4 controls), and eNOS in 40 samples (11 
PV, 12 ET, 17 PMF, plus 4 controls).
Immunocytochemistry/Immunohistochemistry
For cytoplasmatic staining, granulocytes were collected onto microscope glass slides by 
cytospins (2 × 104 cells/each) and fixed by acetone at room temperature (RT). Bone marrow 
biopsy specimens were fixed in 10% neutral formalin solution for 24–36 h, then decalcified 
in EDTA buffer for 3 h and embedded in paraffin. The tissue sections were cut at 5 μm, 
heated at 56°C for 60 min, then deparaffinized and rehydrated through a series of xylenes 
and alcohols followed by an epitope retrieval step. Samples were treated with 3% H2O2 
solution in phosphate buffered saline (PBS) to block endogenous peroxidase activity. The 
next step was incubation with anti-HIF-1α antibody (Abcam) anti-VEGF antibody (BD 
Pharmingen, Cambridge, UK) and anti-eNOS antibody (Santa Cruz Biotechnology) in a 
humidity chamber over night at RT. Immunostaining was performed using the streptavidin-
biotin technique (LSAB+/HRP Kit, DAKO). Immunoreactivity was visualized with DAKO 
Liquid DAB+ Substrate/Chromogen System counterstained with Mayer’s hematoxylin 
(Merck, Whitehouse Station, NJ). For the negative control samples, normal serum and 
trisbuffered saline (TBS) buffer (1:500) were pipetted without primary antibodies. 
Immunoreactive cells were analysed and scored at five powered fields in each sample using 
a computer-supported imaging system (Analysis Pro 3.1) connected to the light microscope 
(Olympus AX70, Hamburg, Germany) with an objective magnification of ×40. 
Immunocytochemical staining for all three angiogenic factors was evaluated in granulocytes 
of 36 cases (11 PV, 10 ET, 15 PMF, plus 4 controls). Immunohistochemical staining was 
performed in granulocytes of total 61 MPN patients, but because of overlapping: HIF-1α 
was evaluated in 36 cases (11 PV, 10 ET, 15 PMF, plus 4 controls), VEGF in 40 cases (15 
PV, 10 ET, 15 PMF, plus 5 controls), and eNOS in 36 cases (10 PV, 11 ET, 15 PMF, plus 5 
controls).
Microarray Analysis
The human oligo probe set was purchased from Operon Human Genome Array-Ready Oligo 
Set Version 4.0 (Eurofins MWG Operon, Huntsville, AL) which contained 35 035 
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oligonucleotide probes, representing approximately 25 100 unique genes. Total human 
universal RNA (HuURNA, BD Biosciences, Palo Alto, CA) served as a universal reference 
control in the competitive hybridization. In microarray studies, for determination of gene 
expression in CD34+ cells we used: eight biological replicates of healthy donors, seven 
biological replicates of PV patients, nine biological replicates of ET patients, and four 
biological replicates of PMF patients. We amplified total RNA from CD34+ cells using the 
Amino Allyl MessageAmp™ II amplified RNA (aRNA) Amplification kit (Life 
Technologies Corp., Carlsbad, CA), according to the manufacturer’s instructions using 300 
ng of total RNA for amplification. The prepared hybridization mixture of cDNA probe and 
aRNA was added on the array in slide and placed in MAUI hybridization chamber 
(BioMicro Systems, Inc., Salt Lake City, UT) and incubated overnight at 42°C. Data 
Filtration, normalization, and analysis were performed as already described [20]. The 
microarray data are available from Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo; accession no. GSE55976).
Statistical Analysis
The one way ANOVA and Dunnett’s posttest were applied using Prism 4 software 
(GraphPad Software Inc., San Diego, CA). The Pearson’s correlation tests were applied 
where appropriate. The results are expressed as the mean ± SEM, and differences at P<0.05 
are accepted as the level of significance.
RESULTS
Angiogenic Factors Gene Expression in Granulocytes and CD34+ of MPN Patients
Using DNA sequencing of 160 MPN patients, JAK2V617F mutation was detected in all PV 
patients and 53% of ET and 61% of PMF patients. CALR mutations type 1 and 2 were 
detected in 69% of ET and 83% of PMF patients negative for JAK2V617F mutation. We 
found that granulocytes of PV patients had significantly reduced HIF-1α gene expression in 
comparison to controls (P < 0.05), as well as PMF patients without JAK2V617F mutation 
(Figure 1A). In CD34+ cells of MPNs and granulocytes of ET patients, the HIF-1α 
expression did not significantly change compared to controls (not shown). In granulocytes of 
MPN patients, VEGF demonstrated decreased expression in ET and PMF patients without 
JAK2V617F and PV homozygous for JAK2V617F mutation (Figure 1B). In CD34+ cells, 
expression of VEGF was significantly decreased in PV and ET patients (P < 0.05, not 
shown). eNOS mRNA levels were generally significantly increased in granulocytes of MPN 
patients (Figure 1C), as well as in CD34+ cells of PMF (P < 0.01, not shown). HIF-1α and 
VEGF gene expression, independently of JAK2 status, did not change significantly in 
granulocytes of MPNs, in contrast to eNOS.
Angiogenic Factor Levels in Circulating Granulocytes and CD34+ Cells of MPN Patients
Angiogenic factors, at protein level, were significantly increased in ET and PV 
independently of JAK2 status (Figure 2A). Our immunoblotting analyses of total HIF-1a 
protein expression revealed a significant increase in granulocytes of MPN patients, 
demonstrating dependence of JAK2V617F mutant allele burden only in PMF (Figure 2B). 
The activated HIF-1α was significantly increased only in nuclear fraction of PV 
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granulocytes (1.73 fold, not shown). Also, VEGF protein levels were increased in PV and 
ET patients, but only significantly increased in JAK2V617F homozygous PMF patients 
(Figure 2C). However, among the PV homozygous JAK2V617F patients, there is a negative 
correlation between VEGF and HIF-1α protein levels (r − 0.969, P < 0.001, Table 1). 
Examination of the eNOS protein levels in granulocytes showed a significant increase of this 
protein in MPN patients (Figure 2D). In addition, among ET patients without JAK2V617F 
mutation, there is a negative correlation between eNOS and HIF-1α protein levels (r − 
0.939, P < 0.05). The increased angiogenic factors were almost generally and significantly 
increased in JAK2V617F positive patients with PMF.
While immunocytochemical analyses of CD34+ cells showed a significant increase of 
angiogenic factors in MPN patients independent of JAK2 mutation (Figure 3A), a negative 
correlation between HIF-1α and VEGF was noted in CD34+ cells among ET patients (r − 
0.797, P < 0.05). Similarly, but less prominent, the percentage of HIF-1α, VEGF-, and 
eNOS-positive cells was significantly increased in granulocytes of MPN patients, except for 
VEGF in PMF (Figure 3B). Increased quantity of angiogenic factor positive cells in 
granulocytes of MPNs was not influenced by JAK2V617F mutant allele burden (Figure 4A–
C). In addition, between VEGF and eNOS there is a significant positive correlation in PV 
(JAK2V617F heterozygous r = 0.536, P < 0.05, homozygous r = 0.723, P < 0.001) and PMF 
patients (JAK2V617F absent r = 0.726, P < 0.001, heterozygous r = 0.709, P < 0.001, 
homozygous r = 0.859, P < 0.001) as well as in JAK2V617F heterozygous ET (r = 0.406, P 
< 0.05, Table 1). While number of HIF-1α-positive cells was increased overall in the MPN 
patients relative to control, except for PMF patients homozygous for JAK2V617F (Figure 
4A), a negative correlation was noted between HIF-1α and VEGF among JAK2V617F 
heterozygous PMF patients (r −0.513, P < 0.05). Interestingly, the immunocytochemical 
analysis of granulocytes of MPN patients showed significant and uniform decrease in 
percentage of the angiogenic factors positive cells after therapy with hydroxyurea (Figure 
5A–C). This decrease in percentage of positive cells was particularly striking in PV patients 
for the angiogenic factors (especially HIF-1α), regarding their increased levels in 
comparison to ET and PMF patients.
Angiogenic Factors Levels in Bone Marrow of MPN Patients
The percentage of HIF-1α positive cells in the cytoplasm of bone marrow stroma cells 
showed a significant increase in JAK2V617F heterozygous PV (Figure 6A). A significant 
increase of HIF-1α positive cells was also observed in bone marrow of PMF patients 
without JAK2V617F mutation (Figure 6A), with decreased levels in the nucleus of MPN 
bone marrow stroma cells (not shown). A significant increase in percentage of VEGF 
positive cells was observed in bone marrow of JAK2V617F heterozygous PV and ET 
patients (Figure 6B). In bone marrow of PMF patients it was evident an increased percentage 
of eNOS, significant in JAK2V617F heterozygous PMF patients (Figure 6C). A significant 
reduction in percentage of eNOS was apparent in JAK2V617F negative ET patients (Figure 
6C). In addition, there is a significant positive correlation between eNOS and VEGF positive 
cells in bone marrow of PMF patients without JAK2V617F mutation (r = 0.703, P < 0.05, 
Table 1). According to presented results, the JAK2V617F mutant allele burden did not 
demonstrate steady influence to angiogenic factors in bone marrow stroma of MPN patients. 
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VEGF, eNOS, and HIF-1α were expressed by the same bone marrow populations: 
megakaryocytes, macrophages, and myeloid precursors that revealed a moderate to strong 
immunostaining intensity in MPNs.
Angiogenesis Related Signaling Pathways in CD34+ Cells of MPN
Using microarray analysis we presented activation of angiogenesis related signaling 
pathways and genes in CD34+ cells of MPNs (Figure 7). We can see that components of 
protein kinase C (PKC), transforming growth factor-beta (TGFβ) and mitogen-activated 
protein kinase (MAPK) signaling pathways were largely activated, while less prominent in 
PI3K/AKT signaling pathway. So, the CD34+ cell proliferation, actin rearrangement and 
migration were stimulated, whereas a cell survival was less affected in MPNs. MAPK1, 
PLCG2, and TGFBR1 gene expression was absent in controls, but increased in MPN CD34+ 
cells (Table 2). Also, SMAD2 and PIK3R1 gene expression was sporadically present in 
healthy controls and increased in MPN CD34+ cells. The statistically significant increase 
was observed for RAC1 (in PMF) and RAC2 (in PV) genes, while reduction for KRAS and 
RAC3 genes (in ET) in comparison to controls. In CD34+ cells of ET, presence of 
JAK2V617F mutation augmented PXN and reduced RAC3 (P < 0.05, not shown) gene 
expression. In PV patients homozygous for JAK2V617F mutation, HIF-1α gene expression 
was further reduced and AKT2 was increased (P < 0.05), although RAC2 and PXN genes 
had increased expression in PV patients heterozygous for JAK2V617F (P < 0.01, not 
shown).
Angiogenic Factor Levels According to Calreticulin Mutation in MPN Patients
To examine does CALR status impact the gene and protein expression of angiogenic factors 
in ET and PMF, we performed parallel studies in accordance to CALR mutations. It has 
been observed that HIF-1α and VEGF mRNA expression has been significantly reduced in 
granulocytes of ET and PMF, not influenced by CALR mutations (Figure 8A). In contrast, 
eNOS mRNA levels were significantly increased in ET regardless of CALR status, but more 
prominent in the absence of CALR mutation (Figure 8A). On the protein level, angiogenic 
factors were generally increased in granulocytes of ET demonstrating significance, except 
VEGF in CALR mutation negative patients (Figure 8B). Only eNOS demonstrated CALR 
mutation dependence, significantly increased (P < 0.05) in ET patients with CALR mutation. 
In PMF patients, only HIF-1α protein has been increased with CALR wild type (Figure 8B). 
Besides HIF-1α and VEGF positive cells, increased eNOS positive granulocytes 
demonstrated significance in CALR mutation positive versus negative ET patients (Figure 
8C). HIF-1α positive granulocytes were also increased in PMF, regardless of CALR status, 
while VEGF positive cells were significantly increased (P < 0.05) in CALR mutation 
negative versus positive PMF patients (Figure 8C). The eNOS positive granulocytes were 
significantly increased in PMF with CALR mutation (Figure 8C). It has been observed 
significantly decreased VEGF and eNOS levels (P < 0.05) in CD34+ cells of ET patients 
with CALR mutation (not shown). Imunohistochemical analysis of bone marrow stroma 
cells of ET and PMF patients revealed that angiogenic factors were not influenced by CALR 
status (not shown).
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We analyzed levels of key angiogenic molecules HIF-1α, VEGF, and eNOS in peripheral 
blood and bone marrow of MPNs and determined their correlation with JAK2V617F 
mutational status and therapy. We found commonly decreased HIF-1α and VEGF gene 
expression in granulocytes while eNOS mRNA levels were generally increased in 
granulocytes of MPNs. Analyses of angiogenic proteins expression showed their significant 
increase in granulocytes of MPN patients. Immunocytochemical analyses of granulocytes 
and CD34+ cells confirmed that the percentages of HIF-1α, VEGF, and eNOS positive cells 
were generally increased, with positive correlation between VEGF and eNOS. 
Immunohistochemical analyses of bone marrow revealed increased percentage of HIF-1α 
positive cells in the cytoplasm of PV patients and decreased in the nucleus of MPN patients, 
while the percentages of VEGF and eNOS positive cells were increased in JAK2 mutation 
positive ET and PMF patients, respectively. The eNOS protein expression demonstrated 
CALR dependence in granulocytes of ET patients, stimulated by the presence of CALR 
mutation.
Patients with PV and PMF showed an increased microvessel density compared to ET or 
healthy controls, while VEGFR-1 protein expression correlated with microvessel density and 
increased VEGF expression in bone marrow of MPNs [21–23]. The bone marrow VEGF 
expression positively correlated with increased serum levels of VEGF in MPNs [18,24]. The 
VEGF concentration was also increased in plasma of patients with ET [25]. Our results 
showed that ET patients, heterozygous for JAK2 mutation, had significantly increased 
percentage of VEGF positive cells in bone marrow. Augmented quantities of neutrophil 
granulocytes have been detected in the peripheral blood and tumor tissues of patients with 
cancers [26], as well as leukocytes and thrombocytes in MPNs [20]. Activated neutrophil 
granulocytes released VEGF and were directly angiogenic by stimulating macrovascular and 
microvascular endothelial cell proliferation and tubule formation [27]. Vice versa VEGF 
recruited the proangiogenic circulating subset of neutrophils that expressed large amount of 
matrix metalloproteinase 9 (MMP-9) that mediates angiogenesis [28]. In our study group, 
VEGF protein expression was generaly increased in granulocytes of MPN patients, reaching 
statistical significance in majority of JAK2V617F defined groups. There is a positive 
correlation between VEGF and eNOS levels in granulocytes of MPNs. VEGF-mediated 
eNOS Ser1177 phosphorylation controlled angioblast and endothelial cells division, 
activating vasculogenesis and angiogenesis [29]. Increased microvessel density, evaluated by 
CD34+ cells, correlated with the absolute number of VEGF positive cells and fibrosis in 
MPNs [12]. According to presented results, the percentage of VEGF positive cells was also 
significantly increased in CD34+ cells of MPN patients. A pathological interaction between 
polymorphonuclear leukocytes and megakaryocytes correlated with myelofibrosis 
development [30].
In the absence of HIF-1α, fewer bone marrow-derived CD45+ myeloid cells are recruited to 
the tumors, decreasing mobilization of VEGF [31]. VEGF negatively correlated with 
HIF-1α in granulocytes of PV and PMF as well as in CD34+ cells of ET in our results. 
Further on, NO increased the VEGF gene expression by augmenting HIF-1 activity [32]. In 
a positive feedback, the VEGF-induced angiogenesis involved NO production from activated 
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eNOS [33]. According to our results, eNOS gene and protein expressions were increased in 
granulocytes of MPN patients, while the percentage of eNOS and VEGF positive cells were 
characterised with a significant positive correlation in granulocytes and bone marrow. 
Activated HIF-1α protein levels were increased in nuclear fraction of granulocytes from PV 
and ET patients. Hydroxyurea treatment reduced erythroid progenitor and CD34+ cells 
growth in PV and ET [34]. The level of VEGF in patients on hydroxyurea therapy were 
significantly lower than in untreated ET patients [13]. Namely, in order to determine changes 
in HIF-1α, VEGF and eNOS positive granulocytes of patients treated with hydroxyurea, we 
found significantly decreased percentage of the angiogenic factors positive cells in MPN 
patients after hydroxyurea treatment.
AKT inhibitor suppressed colony formation from hematopoietic progenitor cells in PMF and 
reduced megakaryocytic burden in bone marrow [35]. PKC-epsilon transgenic mice 
spontaneously developed a myeloproliferative-like disease, with significant increases of 
neutrophils in peripheral blood and bone marrow [36]. Double inhibition of PI3K/AKT and 
mammalian target of rapamycin (mTOR) signaling induced cell-cycle growth arrest and 
apoptosis of CD34+ PMF cells [37]. It has been shown that MPN patients have increased 
peripheral blood and bone marrow plasma levels of both bioactive and total TGFβ1 [38]. 
Moreover, we already demonstrated the increased proinflammatory IL-6 levels in patients 
with MPN [39]. According to our microarray analysis of angiogenesis related signaling: 
proinflammatory PKC, TGFβ, and MAPK signaling pathways demonstrated upregulation of 
related gene members, in contrast to limited anti-inflammatory PI3K/AKT signaling 
pathway.
Patients with JAK2-mutated ET had higher risk of thrombosis and transformation than those 
with CALR-mutated ET. A significant proportion of patients with JAK2-mutated ET, but 
none of those with a CALR mutation, progressed to PV during their clinical course [40]. 
Increased NO levels and activation of eNOS were detected in human umbilical vein 
endothelial cells by CALR stimulation [41], in accordance with our finding that mutated 
CALR stimulated eNOS protein levels and positive cells in ET. The gain of-function 
property of mutant CALR preferentially associated with c-MPL, the TPO receptor, led to 
constitutive activation of AKT and activation of eNOS, demonstrating CALR interaction 
with angiogenic factors [42–44]. Neutrophil elastase cleaves an N-terminus CALR peptide 
characterized as vasostatin, while levels of serum vasostatin in acute myeloid leukemia 
inversely correlated with bone marrow vascularization [45]. Overexpressed CALR 
upregulated the expression and secretion of VEGF and correlated with high microvessel 
density [46].
We showed the angiogenic factors were generally increased in examined tissues of MPN 
patients. Angiogenic factors had more pronounced levels in granulocytes and CD34+ cells, 
than in bone marrow stroma cells, demonstrating the importance of inflammatory 
granulocytes in angiogenesis development. HIF-1α protein expression negatively correlated 
with eNOS and VEGF in granulocytes, while the later two angiogenic factors levels shared 
significant positive correlation in patients with MPNs. The numbers of VEGF, HIF-1a and 
eNOS immuno positive cells were significantly lower in MPN patients after therapy with 
hydroxyurea, and may relates to prolonged survival and better quality of life.
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Abbreviations:
AKT2 v-akt murine thymoma viral oncogene homolog 2
BSA bovine serum albumin
EDTA ethylenediaminetetraacetic acid
eNOS endothelial NO synthase
ET essential thrombocythemia
HIF-1α hypoxia-inducible factor-1a
KRAS kirsten rat sarcoma viral oncogene homolog
MAPK mitogen-activated protein kinase
MMP-9 matrix metalloproteinase 9
MPN myeloproliferative neoplasm
NO nitric oxide
PIK3R1 phosphoinositide-3-kinase regulatory subunit 1
PKC protein kinase C
PMF primary myelofibrosis
PV polycythemia vera
PLCG2 1-Phosphatidylinositol-4,5-bisphosphate phosphodiesterase gamma-2
PXN paxillin
RAC 1/2/3 Ras-related C3 botulinum toxin substrate 1/2/3
SMAD2 SMAD family member 2
TGFβ transforming growth factor-beta
TGFBR1 TGF-beta receptor type-1
VEGF vascular endothelial growth factor
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mRNA expression of HIF-1α, VEGF, and eNOS gene in granulocytes of MPN patients. (A) 
HIF-1α gene expression was significantly reduced in PV heterozygous (htz), homozygous 
(hom), and PMF without JAK2V617F mutation (NM) patients, while (B) VEGF gene 
expression was reduced in PV homo, ET, and PMF NM patients compared to controls (c). 
(C) Increased eNOS gene expression in MPN patients is presented as direct ratio with 
controls using SYBR Green. Values are mean SEM (n = 5–10 patients per individual JAK2 
mutant allele burden: hom, htz, and NM). *P < 0.05, **P < 0.01, and ***P < 0.001.
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Expression of HIF-1α, VEGF, and eNOS proteins in granulocytes of MPN patients 
determined by immunoblotting. Densitometry revealed increased protein expression of (A) 
angiogenic factors in MPNs; (B) total HIF-1α in MPN patients heterozygous (htz), 
homozygous (hom), and no JAK2V617F mutation (NM, n = 6 patients per individual JAK2 
mutant allele burden); (C) VEGF in htz, hom, and NM (n = 5–9); (D) eNOS proteins in htz, 
hom, and NM (n = 5–7) of MPN patients compared to controls (c, n = 4). Values are mean ± 
SEM. *P < 0.05, **P < 0.01, and ***P < 0.001.
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Immunocytochemical analysis of angiogenic factors positive cells in CD34+ cells and 
granulocytes of MPN patients. The percentage of angiogenic factors showed a significant 
increase in (A) CD34+ cells (n = 5 per individual MPN) and (B) granulocytes of ET, PV, and 
PMF patients (n = 10–15). Values are mean ± SEM. *P < 0.05, **P < 0.01, and ***P < 
0.001.
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Immunocytochemical analysis of angiogenic factors positive cells in granulocytes of MPN 
patients according to JAK2V617F mutant allele burden. Quantitative analysis of (A) 
HIF-1α, (B) VEGF, and (C) eNOS percentage of positive cells in granulocytes revealed its 
significant increase in MPN patients heterozygous (htz), homozygous (hom), or no 
JAK2V617F mutation (NM) versus controls (c), n = 5–6 patients per individual JAK2 
mutant allele burden and controls. Values are mean ± SEM. **P < 0.01.
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Immunocytochemical analysis of angiogenic factors positive cells in granulocytes of MPN 
patients after at least 6 months therapy with hydroxyurea (HU). A significant decrease in 
percentage of (A) HIF-1α, (B) VEGF, and (C) eNOS positive cells in ET, PV, and PMF (n = 
3× 6 patients before and after therapy with HU). Values are mean ± SEM. ***P < 0.001.
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Immunohistochemical analysis of angiogenic factors positive cells in the bone marrow of 
MPN patients. (A) Increased percentage of cytoplasmatic HIF-1α positive cells is apparent 
in PV htz and PMF no JAK2V617F mutation (NM) patients presented in adjacent 
immunohistochemical graphs. (B) It has been detected a significant increase in percentage of 
VEGF positive cells in ET htz and decrease in PV htz patients, while (C) eNOS positive 
cells are increased in PMF htz patients and reduced in ET NM patients versus controls (c). 
Arrows indicate positive brown cells. Corresponding controls are at the bottom left corner of 
immunohistochemical graphs. Bar 50 μm. Values are mean ± SEM (n = 5–6 patients per 
individual JAK2 mutant allele burden). *P < 0.05, **P < 0.01.
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Angiogenesis signaling pathway in CD34+ cells of MPN origin. (+p) phosphorylation, → 
stimulation; empty boxes represent downregulated, gray boxes no changed and black boxes 
upregulated genes versus control (corresponding to Table 2).
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Expression of angiogenic factors according to CALR status in granulocytes of MPN 
patients. (A) HIF-1α and VEGF gene expression were significantly reduced in PV and PMF, 
while eNOS gene expression (presented as direct ratio with controls using SYBR Green) 
was increased in ET. (B) Increased angiogenic factors protein expression in ET determined 
by Western blot. (C) Increased levels of angiogenic factors positive cells in ET and PMF 
determined by immunocytochemistry. Values are mean ± SEM (n = 4–5). *P < 0.05, **P < 
0.01, and ***P < 0.001.
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